Eslicarbazepine acetate
Sponsors
Sumitomo Pharma America, Inc., Bial - Portela C S.A., King Edward Medical University
Conditions
Bipolar I DisorderEpilepsyEpilepsy With Partial On-set SeizuresEpilepsy With Simple or Complex Partial Onset SeizuresFocal-Onset SeizuresNeuropathic PainPainful Diabetic NeuropathyPartial Epilepsy
Phase 1
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
CompletedNCT00900237
Start: 2008-11-30End: 2009-02-28Updated: 2014-12-19
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
CompletedNCT00971295
Start: 2007-10-31End: 2008-09-30Updated: 2014-12-16
Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects
CompletedNCT00987558
Start: 2009-06-30End: 2009-08-31Updated: 2015-01-13
The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients
TerminatedNCT01878578
Start: 2002-11-30End: 2003-03-31Updated: 2014-02-27
Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.
CompletedNCT02283801
Start: 2006-11-30End: 2007-01-31Updated: 2014-11-05
Phase 2
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy
CompletedNCT00980746
Start: 2007-11-30End: 2008-11-30Updated: 2016-06-22
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
CompletedNCT00981227
Start: 2007-11-30End: 2009-01-31Updated: 2014-10-29
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder
CompletedNCT01822678
Start: 2005-12-31End: 2006-11-30Updated: 2014-03-27
Phase 3
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
CompletedNCT00866775
Start: 2009-04-30End: 2013-05-31Updated: 2016-03-11
Eslicarbazepine Acetate Monotherapy Long Term Study
CompletedNCT00910247
Start: 2009-08-31End: 2017-04-15Updated: 2018-07-17
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
CompletedNCT00957047
Start: 2004-07-31End: 2008-01-31Updated: 2025-03-25
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
CompletedNCT00957684
Start: 2004-07-31End: 2007-02-28Updated: 2025-03-12
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
CompletedNCT00957372
Start: 2004-12-31End: 2008-06-30Updated: 2014-07-02
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
CompletedNCT00988156
Start: 2007-12-07End: 2017-08-24Updated: 2018-11-13
Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
CompletedNCT01422720
Start: 2010-04-30End: 2013-09-30Updated: 2017-08-07
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
WithdrawnNCT03108729
Start: 2017-07-06End: 2017-10-26Updated: 2018-01-16
Phase 4
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
CompletedNCT03116828
Start: 2017-07-07End: 2019-06-06Updated: 2020-06-16
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
CompletedNCT03116828
Start: 2017-07-07End: 2019-06-06Updated: 2020-06-16